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The Division of Tuberculosis Elimination (DTBE) was saddened to learn of the 
unexpected death of our former colleague, Dr. ShaJuan Colbert, who passed away in 
early February. She had worked in DTBE’s Communications, Education, and Behavioral 
Studies Branch (CEBSB) before taking a detail to the NCHHSTP Office of Health 
Equity. Please see the Personnel Notes section for further details. 
 
On December 8–9, 2011, the first semi-annual meeting of the newly constituted 
Tuberculosis Epidemiologic Studies Consortium (TBESC) took place in Atlanta.  On 
January 14, 2012, the fourth bi-annual Southeastern Mycobacteria Meeting took place 
in Atlanta. Reports about these important meetings are included in this issue. 
 
As you know, DTBE science staff developed guidelines for the use of a 12-dose 
combination regimen of isoniazid and rifapentine for latent TB infection; these guidelines 
were released on December 9, 2011, in CDC’s Morbidity and Mortality Weekly Report 
(MMWR). In preparation for that release, DTBE’s CEBSB developed and updated a 
variety of education and communication materials. Please see the related article in this 
issue, which includes links to these useful materials. 
 
Each year on March 24, CDC and others around the world observe World TB Day. On 
this day, we commemorate the date when Robert Koch announced his discovery of the 
bacillus that causes tuberculosis (TB). Around the world, TB programs, civic groups, 
non-governmental organizations, and others participate in World TB Day activities to 
raise awareness about their TB-related problems and solutions, and to support 
worldwide TB control efforts. This year, CDC joins the global Stop TB Partnership in 
adopting the slogan “Stop TB in my lifetime,” calling for a world free of TB.  This theme 
encourages people all over the world, from the youngest to the oldest, to make an 
individual call to stop TB and to say what changes in TB treatment and prevention they 
expect in their lifetimes. 
 
For examples of past World TB Day events, links to World TB Day planning resources, 
fact sheets, posters, and other materials that may be of assistance to you in your World 
TB Day activities, please visit the World TB Day section on the DTBE Website at 
http://www.cdc.gov/tb. These and other materials may be obtained according to the 




The CDC observance of World TB Day will be held on March 22 at CDC’s Roybal 
campus, in collaboration with our colleagues in the CDC Center for Global Health. In 
addition, the fact that March 24 falls on a Saturday this year works out well for the 
organizers of the Atlanta TB Awareness Walk. This energizing event, held in Atlanta’s 
Grant Park, is now in its sixth year.  More information about these events will be 
provided in the next issue of TB Notes. 
 
If you are planning an event around World TB Day, we would like to hear about it. As 
soon as your event is planned, please send a completed event form by e-mail to Ms. 
Ijeoma Agulefo at iaa1@cdc.gov. Please contact Ije if you do not have an event form. 
We will post these activities on the World TB Day section of the DTBE web site. 
 
I look forward to hearing and reading about the creative and resourceful activities many 





      Kenneth G. Castro, MD 
Assistant Surgeon General, USPHS, & 
Commanding Flag Officer 
CDC/ATSDR Commissioned Corps 
Director, Division of Tuberculosis Elimination 
National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention
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HIGHLIGHTS FROM STATE AND 
LOCAL PROGRAMS 
 
Amistad Binational TB Project 
 
On October 6, 2011, Dr. David L. Lakey, 
Commissioner for the Texas Department of State 
Health Services, and Dr. Raymundo S. 
Verduzco-Rozan, Secretary of Health for the 
State of Coahuila, Mexico, came together with 
citizens from the states of Texas and Coahuila to 
sign a joint statement of cooperation.  The 
signing of this statement was the official 
beginning of their collaboration in a project that 
will be called the Amistad Binational Tuberculosis 
Project.  Dr. Sandra Guerra, Director, Texas 
Health Service (THS) Region 8, was the host of 
the signing ceremony that was held in Del Rio, 
Texas.  The Amistad TB Project will be a 
collaborative effort between THS Region 8; the 
Texas cities of Del Rio and Eagle Pass; and the 
Coahuila city of Piedras Negras in Mexico. Ms. 
Rita Espinoza will be the Region 8 point of 
contact for the Amistad Binational TB Project. 
 
 
Dr. Lakey and Dr. Verduzco-Rozan signing the 
binational agreement. 
 
In addition to Drs. Lakey, Verduzco-Rozan, and 
Guerra, several other U.S. and Mexican officials 
were present. These included Julia S. Goldberg, 
M.P.H., Acting General Manager, U.S. Section, 
U.S.-Mexico Border Health Commission; Dr. 
Francisco Elizalde Herrera, Undersecretary of 
Health of the State of Coahuila; Dr. Maria Teresa 
Zorrilla Carcaño, Mexico Section Secretary, U.S.-
Mexico Border Health Commission; and Dr. R. J. 
Dutton, Director, Texas Dept. of State Health 
Service Office of Border Health. 
 
The agreement between the two states declares 
their intentions to: 
 
• Respect the standards, procedures, laws, 
and needs of each state, while striving to 
reduce the burden of TB along the Texas-
Coahuila border; 
• Work cooperatively to pursue joint 
opportunities to effectively address TB 
prevention and control across our shared 
border; 
• Form a Bi-state Steering Committee on TB to 
seek opportunities for our respective states 
to work collaboratively to ensure a reduction 
in the mortality, morbidity, and transmission 
of TB across our shared border; and 
• Request support of the U.S.-Mexico Border 
Health Commission in order to ensure the 
most effective and efficient use of the 
resources assigned by each participant for 
the execution of TB prevention and control 
as described in the agreement. 
 
—Submitted by Charles Wallace, PhD, MPH 
Manager, Tuberculosis Services Branch 
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TB Experiences in “Sin City”: 
Collaborating with Corrections 
Workers in Las Vegas 
 
Introduction 
Public Health Advisors (PHAs) encounter many 
different challenges and experiences in the field.  
My own personal experience in moving back 
west to Las Vegas, also known as “Sin City” and 
“Lost Wages,” has been filled with many new 
experiences and new opportunities to learn about 
TB. Although my role as a PHA for the Southern 
Nevada Health District (SNHD) consists of 
various day-to-day activities and duties, my main 
role since arriving in Las Vegas has been 
working with and educating private physicians, 
providing assistance in contact investigations in 
hotel/casinos, and working as a liaison for the 
area’s correctional facilities. The latter has 
definitely been a “new TB experience” and is the 
focus on this report. 
 
In working with the SNHD’s TB clinic activities, I 
have come to understand that my greatest 
opportunity for making a difference here is to 
serve as a liaison, strengthening the local health 
department through communication with outside 
health care providers. Thus, I have been working 
with correctional health care staff to improve 
working relationships and to increase 
collaboration between the agencies. Ideally, 
increasing this communication will eventually 
improve case reporting, as well as the exchange 
of information about case management. In 
addition, effective communication and improved 
cooperation with correctional facilities staff will 
improve TB screening practices in facilities and 
will ensure continuity of care and completion of 
treatment. Therefore, my main function in Clark 
County will be to strengthen communications with 
these outside providers. 
 
Procedures/Activities 
During my first few weeks at SNDH, I researched 
and reviewed the local state policies and 
regulations in relation to TB control in 
correctional facilities. Based on guidelines from 
CDC (“Prevention and Control of Tuberculosis in 
Correctional and Detention Facilities,” CDC; 
MMWR) and supporting documentation in the 
Nevada Administrative Codes, I drafted a 
correctional liaison agreement for the SNDH and 
all of the Nevada correctional facilities. After 
discussing the agreement with the SNHD nursing 
managers and supervisor, we concluded that this 
agreement should be adjusted and tailored to 
each facility, since the facilities vary by capacity, 
average length of time inmates spend in facility, 
number of prior TB cases and population, 
screening process, etc. Before proceeding with 
tailoring each facility agreement, I contacted 
each facility’s medical nursing supervisor to 
schedule a tour of their facility and conducted a 
brief assessment of their current TB screening 
policy and practices. My goal was to better 
understand each site’s current screening method 
and discharge process, from the time the 
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detainee is brought in, all the way through their 
release or transfer. 
 
I started my first full assessment with Clark 
County Detention Center (CCDC).  Upon my 
arrival at CCDC, the nursing supervisor greeted 
me in the lobby and escorted me to the booking 
area.  This area seemed as busy as an 
emergency room waiting area in the early 
morning hours. I was shown their databases for 
screening assessment and for placement and 
reading of tuberculin skin tests (TSTs). CCDC 
tests every inmate coming in. When I asked for 
documentation of TST readings, they showed me 
a list of inmates with their locations in the facility 
and who was scheduled for a reading on that 
date.  The readings are done by the Medical 
Assistant. 
 
As we walked through the facility’s hallways, we 
occasionally crossed line-ups of inmates facing 
the wall. I was next taken to the medical floor, 
where the negative-pressure rooms are located. 
There are also medical offices, a dental services 
area, and a nurse’s station (similar to a nurse’s 
station in a hospital). There I was introduced to 
the rest of the medical staff.  I concluded my visit 
by suggesting follow-up in-service training and 
the possibility of my revisiting the facility at a 
future date. 
 
Two weeks from my initial tour at CCDC, I was 
back. This time my mission was to “shadow” the 
nurses and observe their booking and screening 
procedures, as well as their TST reading 
techniques. I was in booking from approximately 
8:30 am to 12:00 noon.  It was quite a scene: I 
observed inmates yelling “Officer!” and banging 
hard on their cell doors; saw officers running and 
attempting to catch a troubled detainee; and 
heard officers yelling at the crowd in the booking 
area that they all had to sit down and raise a 
hand if they needed the restrooms or the phones. 
 
I shadowed three busy nurses working in booking 
who were all conducting initial medical 
assessments and asking questions about 
medical history data, including questions about 
behavioral issues such as suicide risk and drugs 
habits. There were only a few TB-related 
questions: TST history, chest X-ray history, and 
symptoms.  In addition to the questionnaire 
assessment, the nurses took vital signs and 
placed TSTs. 
 
Once I was finished in booking, I went upstairs 
with the Medical Assistant, who showed me the 
inmates’ quarters and dorms.  Armed with a list 
of inmates by location, the Medical Assistant and 
I visited the different floors.  Each floor had a 
different designation; for example, female 
inmates had their own floor. Also, gang-related 
inmates were kept separate according to their 
gang to avoid confrontations. I learned that more 
guards were needed on these floors, owing to 
this highly violent population. There was an 
inmate on this floor whose TST reaction needed 
to be read, and the Medical Assistant and I 
entered the cell to read it. As we went into the 
cell, an additional guard entered behind us. We 
visited “open” areas where the inmates were 
called out by the guard from a list of inmates we 
were seeking for TST readings.  These readings 
were done mainly during afternoon hours, since 
many of the inmates were in court during the 
morning hours.   
 
Results of Activities 
During the time spent in booking, I noticed a few 
technical issues with mishandling and storage of 
the tuberculin vials.  The nurses in the booking 
area all had their own tuberculin vials; however, 
of the three tuberculin vials in use, only one was 
marked with the date on which it was opened. 
One of the nurses mentioned that they place 
approximately 125 to 150 TSTs daily, and one 
vial lasts about 2 days.  I noted that the 
tuberculin vials were not insulated or protected 
from the light; they were kept on the nurses’ 
desks near their computer screens. 
 
A few other techniques were handled differently 
by all three nurses.  For example, while one 
nurse was placing TSTs properly, the others 
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were placing them sometimes a bit too deeply 
and sometimes too shallowly. At one point, I saw 
tuberculin dripping from a detainee’s arm. 
In the booking area, I observed an opportunity for 
improving the screening process. A detainee who 
was being transferred in from another facility 
mentioned that he had recently had a TST placed 
at the City of Las Vegas Detention Center (thus 
he was still within the 72-hr. period). It was 
obvious that his skin test reaction was positive. 
When the detainee was not interviewed further 
about his positive reaction, I asked the detainee 
more information on when and where he 
received his skin test, and about possible 
exposure, e.g., if he knew anyone with TB. I 
located a ruler with the assistance of another 
health care worker. We then read his skin test 
and documented the reading, although according 
to the nurse in booking, they normally do not do 
any readings at booking, per their CCDC 
procedures. Most readings are done by Medical 
Assistants. 
 
When observing the Medical Assistants reading a 
TST, I noted that they were wearing gloves. 
Normally, wearing gloves is standard procedure; 
however, gloves hinder the touching or palpating 
of an inmate’s arm, and one’s sensitivity to an 
induration is reduced. I further noticed that 2 out 
of 10 TSTs were not read owing to inmates being 
discharged after their court hearings.  This 
problem could be reduced by scheduling a 
morning round of readings before court. 
 
Lessons Learned 
I experienced the booking process and the TST 
reading procedures in a correctional facility 
setting for the first time in my TB career.  This 
experience allowed me to better understand the 
“correctional world,” and also learn about 
correctional TB screening procedures.  
Observing the frequent movement of inmates 
between various facilities and the court system 
provided me with the valuable perspective of how 
challenging it is to work with inmates and with the 
inmate release process. It is my hope that Clark 
County Detention Center management can 
improve the screening policies and procedures 
and also provide staff training.  At the same time, 
we at SNHD will work with the corrections system 
by attempting to follow up on inmates who start 
TB treatment in the correctional system.   
 
Future Plans 
After my experience at Clark County Detention 
Center, I followed up with the Nurse Manager at 
the facility by sending her an e-mail summarizing 
my observations and recommendations. We 
scheduled tentative dates for TST in-service 
refresher training for her booking staff, which is 
composed of nightshift nurses, dayshift nurses, 
and Medical Assistants. We scheduled an early 
morning (6 am) short presentation for the 
nightshift workers, and another in-service training 
for the dayshift staff.  I also plan to develop and 
implement a general TB 101 course or a TB 
infectiousness course for the corrections officers, 
to educate them on TB transmission and to teach 
them how to detect inmates with TB symptoms. 
 
I’m planning to conduct similar activities for the 
other SNHD correctional facilities. I will continue 
working on an informal agreement between 
SNHD and the other facilities, and I will review 
their current infection control plans and their TST 
policies. 
 
Although I was on this TB assignment only a 
short time as of this report, I can say that it has 
definitely been a fruitful experience packed with 
new challenges that have put my PHA skills to 
work. 
 
—Reported by Maria Galvis 
CDC PHA assigned to Las Vegas, NV 
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2012 National TB Controllers 
Association Awards Open for 
Nominations! 
 
This is the third year the National Tuberculosis 
Controllers Association (NTCA) will be honoring 
individuals or organizations for their dedication 
and distinguished service in the field of 
tuberculosis.  Nominations can be submitted by 
anyone and nominees do not need to be 
members of NTCA.  The award categories are 
described below. Nomination forms must be 
submitted by April 2, 2012. The awards will be 
presented at the 2012 National TB Workshop, 
being held in Atlanta June 12–14. Submit 
nominations by e-mail to either of the NTCA 
Awards Committee Co-Chairs: 
Shea Rabley, rableyss@dhec.sc.gov, or Peter 
Davidson, davidsonp@michigan.gov 
 
NTCA Award Categories: 
TB Controller of the Year – This is the National 
Tuberculosis Controllers Association’s highest 
award.  It recognizes an outstanding contribution 
and impact on tuberculosis prevention and 
control at the local, state, regional, or national 
level. The award recognizes what TB controllers 
are all about.  
 
NTCA Presidential Award – The current NTCA 
President selects the recipient of this award to 
acknowledge special accomplishments of an 
individual or organization that has made an 
outstanding contribution to the NTCA or the TB 
community. 
 
Carol Pozsik Nursing Award – This award honors 
exemplary care, service, dedication, or 
leadership in the field of TB nursing.  
 
William Stead Clinician Award – This award 
recognizes outstanding commitment and 
performance by a clinician providing tuberculosis 
care, leadership, or mentoring.   
 
Ed Desmond Award – This award honors 
exemplary service, dedication, or leadership to a 
tuberculosis laboratory professional.      
 
Robert Koch Award – This award recognizes an 
outstanding contribution with a clinical, 
epidemiological or academic focus by a 
tuberculosis researcher in the quest for 
eliminating tuberculosis.   
 
Dixie Snider Award – This award recognizes a 
CDC employee who has provided outstanding 
support, through partnership with a state or local 
tuberculosis community, in the interest of 
tuberculosis control and prevention. 
 
Charles DeGraw Advocacy Award – This award 
recognizes an individual that has made an 
outstanding effort or achievement in advocating 
for increased support and recognition of 
tuberculosis control and prevention efforts. 
 
Joe Ware Partner Service Award – This award 
recognizes an organization that has made a 
significant effort and/or contribution to the 
mission of tuberculosis control and prevention 
through advocacy and partner activities. 
 
The form on the next page can be copied and 
used for nomination write-ups.  
 
—Reported by Shea Rabley and Peter Davidson 
NTCA Awards Committee Co-Chairs  
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National TB Controllers Association 
2012 Award Nomination Form 
Nomination Deadline – April 2, 2012 
 
Nominee’s Name __________________________________________________ 
 








Will your nominee be attending the 2012 National TB Controllers Conference? _____ 
 






In the space below, describe the professional background and merits of nominee which 
meet the award criteria/description.  Attach additional pages as necessary. 
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Evaluation of the National 
Tuberculosis Indicators Project 
 
Background: In 2006, CDC identified 15 high-
priority TB control activities as national TB 
program objectives. The National Tuberculosis 
Indicators Project (NTIP) is a secure web-based 
system established in 2009 to monitor the 
progress of state and local TB programs toward 
meeting these objectives. NTIP generates 
reports for each objective using data already 
submitted by programs as part of routine TB 
surveillance. In collaboration with the National 
Tuberculosis Controllers Association (NTCA), we 
conducted an evaluation to examine how 
programs use NTIP and to understand how 
surveillance data reporting affects NTIP.  
 
Methods: In September 2011, NTCA distributed 
an online survey about NTIP to all TB controllers 
and registered NTIP users, representing 50 state 
and 18 major city or territorial TB programs. We 
also conducted interviews with CDC NTIP staff 
and NTIP users about the structure and function 
of NTIP. 
 
Results: Of 406 people surveyed, there were 122 
responses from 38 out of 50 (76%) state and 10 
out of 18 (56%) major city or territorial TB 
programs. The most common job positions of 
survey respondents were TB program manager 
(35%), TB epidemiologist (27%), and TB 
controller (20%).  Respondents were most 
commonly from programs that had 100–500 
confirmed TB cases in 2010 (36%) or less than 
50 cases (35%).  
 
Responses on the uses of NTIP 
The responses indicated that 41% use 
information from NTIP reports either monthly or 
quarterly, while 7% use it daily or weekly and 
27% use it once or twice a year.  A majority of 
programs (61%) currently use NTIP reports in 
addition to their own indicators to guide program 
activities. However, one quarter of respondents 
said they do not use information from NTIP 
reports at all, and instead use their own program 
data.   
 
Programs most commonly use NTIP for 
preparing interim/annual reports to CDC (58%), 
summarizing surveillance and/or program data 
(57%), and checking the completeness and 
accuracy of data reported to CDC (52%). Of 
these uses, respondents identified summarizing 
surveillance and/or program data as the most 
helpful aspect of NTIP to their current work. The 
respondents also indicated that their ability to use 
NTIP effectively would be enhanced by more 
training on using the NTIP system (43%), more 
information about NTIP (36%), and further 
training on the national TB program 
objectives/performance targets and their 
rationale (34%).  
 
Responses on surveillance data reporting and 
NTIP 
Approximately one third of respondents stated 
that the lack of current or accurate surveillance 
data is the largest barrier to using NTIP 
effectively. Difficulties transmitting data to CDC 
have led to discrepancies in the data presented 
in NTIP reports compared to programs’ own data. 
Overall, 40% of respondents reported problems 
uploading surveillance data from their system to 
CDC since 2009. Only 7% of respondents 
estimated that the data in NTIP reports matched 
completely with their own program data. Nearly 
half of the respondents answered that the data 
matched 60%–80% of the time, 12% felt the data 
matched 20%–40% of the time, and 1% stated 
that nothing matched. One third of respondents 
reported that NTIP has helped them identify 
problems with the accuracy of their own 
surveillance data. 
 
The majority of respondents indicated their 
program uses a CDC-developed system (the 
National Electronic Disease Surveillance System 
[34%] or the electronic Report of Verified Case of 
Tuberculosis application [27%]) to transmit TB 
surveillance data to CDC. Other respondents use 
a commercially purchased system (14%) or a 
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system developed in-house by the TB program 
(14%). A greater proportion of respondents using 
commercially purchased or TB program 
developed systems had problems transmitting 
data when compared to those using CDC-
sponsored systems (Figure 1).  
 
Figure 1. Percentage of survey respondents 
reporting TB surveillance data transmission 
problems by data system type, United States, 
2009–2011. 
 
Figure 1 shows the percentage of respondents 
reporting data transmission problems, by data 
system type. Only 36% of those using CDC-
sponsored systems to transmit TB case data 
reported problems, while 59% of those using in-
house systems and 82% of those using 
commercially purchased systems reported 
problems. 
 
Discrepancies can also occur between NTIP 
reports and local calculations if different data 
sources or different calculation methods are 
used. Several respondents pointed to these 
discrepancies as a reason NTIP reports are not 
more useful to them locally. In addition to 
discrepancies between NTIP data and local 
program data, respondents also pointed out 
discrepancies between NTIP and National TB 
Surveillance System data (NTSS). NTIP 
automatically pulls data from CDC’s dynamic 
surveillance databases every week. Once the 
NTSS dataset is “frozen” in the spring of each 
year, any changes, corrections, or additions to 
cases counted in previous years will be reflected 
in NTIP, but will not be updated in NTSS until the 
following spring. In 2009 and 2010, these 
discrepancies were complicated when data for 
three states were manually corrected in NTSS, 
but not in NTIP. No manual corrections will be 
necessary in the future, so this source of 
discrepancies should not recur.  
 
Conclusions: Ensuring that programs are able to 
transmit TB surveillance data in an accurate and 
timely manner will allow NTIP to track their 
progress toward meeting national TB objectives. 
This information can be especially useful to 
programs with insufficient epidemiologic support 
to develop and calculate their own indicators. If 
significant discrepancies exist between data 
received at CDC and program data, NTIP will not 
be able to help programs evaluate their 
performance.  
 
The following aspects of NTIP can benefit from 
further examination: 
1. Timeliness and accuracy of surveillance data 
transmission 
NTIP reports only contain information on TB 
cases already transmitted to CDC.  Programs 
must be able to submit cases to CDC in a 
timely manner in order to have up-to-date 
reports. State and local TB programs can 
continue to work toward ensuring that they 
have complete and accurate data on all TB 
cases in their jurisdiction. Depending on 
when data are submitted to CDC, programs 
can then know the best time to generate 
NTIP reports. CDC can continue to support 
programs, especially those with in-house or 
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commercially purchased data systems, to 
ensure correct data transmission. 
 
2. Opportunities to assist programs to use NTIP 
reports 
Programs have identified factors that explain 
why current NTIP methods used to calculate 
indicators can misrepresent the status of 
their programs. There must be an 
understanding as to how indicators are 
measured at the national level. CDC should 
expand communication and education about 
NTIP to ensure programs understand how 
NTIP reports are generated. Finally, 
continuing to respond to feedback from local 
and state TB programs about their 
experiences with NTIP and the national TB 
objectives will help guide future 
improvements. 
 
—Reported by Robert Luo, MD, MPH, EIS Officer, 
Kai Young, MPH, and Adam Langer, DVM, MPH 
Div of TB Elimination, and 
Charles Wallace, PhD, MPH 
Texas Dept of State Health Services 
 





REACH is a non-profit organization based in 
Chennai, India, that has been dedicated to the 
fight against TB in India for more than 10 years. 
The REACH Lilly MDR-TB Partnership Media 
Program is an initiative of REACH, supported by 
the Lilly MDR-TB Partnership. (The Lilly MDR-TB 
Partnership is a public-private initiative led by Eli 
Lilly and Company. It is working to address the 
expanding crisis of multidrug-resistant (MDR) TB 
together with 17 global health and development 
organizations, academic institutions, and private 
companies.) REACH aims to harness the power 
of media to inform the public about preventing, 
controlling, and curing TB. In November 2011, 
the Program announced a short film competition 
for Indian filmmakers, TB Tales.  
 
The competition did not require an entry fee and 
was open to all filmmakers across India, 
including students, amateur and professional 
filmmakers, and health care providers. Entries 
had to be between 30 seconds and 5 minutes 
long, with dialogue either in English or with 
English subtitles. Silent films, often more 
powerful than those with dialogue, were also 
eligible. All styles — e.g., fiction, documentary, 
drama, docudrama, animation — were 
welcomed. Any format, including films shot on 
mobile phones, would be considered.  
 
The top three entries will receive citations and 
cash awards; the first-place prize (in rupees) is 
Rs 30,000 (about $600 USD), second place is Rs 
20,000 (about $400 USD), and third place is Rs 
10,000 (about $200 USD). REACH plans to 
feature the top 10 films on a dedicated YouTube 
channel. 
 
The competition closed on January 15. A total of 
24 entries, in several different languages, were 
received. Jury members include Suriya, actor; 
Gautham Menon, film director; Dr. P R 
Narayanan, Former Director, Tuberculosis 
Research Centre; Blessina Kumar, activist and 
Vice Chair, Stop TB Partnership Board; and Dr. 
Subhash Yadav, Technical Officer, The Union 
Southeast Asia Regional Office. An 
announcement of the winners is anticipated by 
February 15.  
 
“We hope that this initiative, supported by the 
Lilly MDR-TB Partnership, will help improve 
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understanding about this disease, thereby 
providing accurate information to TB patients and 
connecting them to services,” said Dr. Nalini 
Krishnan, Director, REACH. Added Anurag 
Khera, Director, Corporate Affairs, Eli Lilly and 
Company (India): “We believe that the graphic 
power of films can change perceptions and 
influence behavior. Films can be a very useful 
and effective medium for attaining and supporting 
our quest for better TB care and control.”  
 
To learn more about REACH and to view the 
winning and short listed films, visit Speak up to 
Stop TB at http://media4tb.org/index.html. 
 
—Submitted by Linette McElroy 
TB ETN 
 
TB Rough Riders 
 
Pictured left to right: Debbie Williams, Diana 
Fortune, Ayesha Bashir, Sarah Yazzie. Photo 
taken at sunset at Canyon de Chelly, Arizona.  
 
The TB Rough Riders blazed a trail (in our Ford 
Bronco), November 28–December 2, 2011, 
through the Navajo Nation. The intrepid four 
provided TB education for 86 health 
professionals including clinicians, hospital and 
clinic nurses, and TB staff, in eight service units 
crossing two states and one nation, covering 
over 1200 miles.  
 
Sarah Yazzie, Navajo Nation TB Program 
Manager, partnered with the New Mexico (NM) 
Department of Health and the Arizona (AZ) 
Department of Health to provide TB education to 
all eight Navajo Nation Service Units to address 
an increase in TB morbidity and mortality across 
the Navajo Nation.  The presentations were given 
by Ayesha Bashir, MD, and Debbie Williams, RN, 
from the AZ Department of Health, and Deborah 
Isaacks, RN, BSN, and Diana Fortune, RN, BSN, 
from the NM Department of Health. Each 2-hour 
session included TB 101, TB Infection Control 
Practices, How to Become TB Lab Savvy, TB 
Contact Investigation Strategies, and TB Nurse 
Case Management. 
 
The on-site educational campaign is part of an 
overall effort by the Navajo Nation and the NM 
Department of Health to address the increased 
TB mortality that was noted during the 2007–
2009 study completed in New Mexico. Navajo 
patients were one of two groups identified as 
high risk for TB mortality. The study cited two 
reasons that related to increased risk: 1) patient 
delay in seeking treatment and 2) delay in 
clinician diagnosis. 
 
The TB Rough Riders will continue to collaborate 
to address TB throughout the Navajo Nation. 
 
—Reported by Diana Fortune, RN, BSN 
TB Nurse Consultant 
and TB Program Manager (acting) 
NM Department of Health 
 
They Go to Die: 
Portrayal of the TB/HIV Epidemic 
Among Mine Workers in South Africa  
 
Jonathan Smith says he is not a film maker; he’s 
a researcher – an epidemiologist to be exact. 
But, the buzz created by the screening of his 
short documentary, They Go to Die, at the 42nd 
UNION World Conference on Lung Health in 
Lille, France, in October 2011 suggests he might 
be both.  
 
The work-in-progress film is a real-life account of 
Smith’s journey as he learns about the 
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devastating impact of the South African gold 
mining industry on the TB/HIV epidemic there, 
and the blatant human rights violations that these 
workers face. As he sorts through a century of 
documented research on the issue, he comes to 
the sober realization that any further research on 
the issue will fail to enact change. Thus he 
begins his quest to find the mineworkers affected 
by this process.  
 
Initially only driven by the data that highlight the 
importance of this issue, Smith travels to rural 
South Africa to live among and get to know four 
ex-miners and their families. He quickly discovers 
that their lives are more complex than simply 
“numbers” that fill the pages of an academic 
journal. As the film follows the never-before-seen 
lives of these miners, the viewer is made aware 
of the challenges that each miner faces in health 
and family life, and witnesses Smith’s personal 
change as he overcomes cultural differences to 
create a personal bond with the men and their 
families. Despite this revolution, the film ends 
with the reality of the health situation of these 
men, and brings to life the gripping reality and 
importance of lack of access to essential 
medicines. 
 
“Simply portraying an epidemic through the lens 
of a camera has been done before and continues 
to have limited effectiveness, even when those 
affected are the ones speaking about the disease 
and telling their personal stories. But if we turn an 
epidemic into an emotion, then we motivate 
change,” says Smith. 
 
They Go to Die explores the epidemics in the 
broader context of human life, instead of through 
only a narrow context of disease. It portrays the 
life of the individual as a whole, not solely the 
disease by which they are affected. It surfaces 
issues of health, human rights, and legal issues 
in the form of human relationships. In doing so, 
the film creates both a cathartic and educational 
experience. As a viewer from the rough-cut 
screening observed, “The strength of [the film] is 
that it doesn’t focus on disease and death, but 
rather the lives that TB and HIV take away.” 
 
In October 2011, Smith received an international 
award for his documentary and website.  He was 
awarded the Tuberculosis Survival Prize at an 
awards ceremony in Lille, France. The annual 
award is given by the Tuberculosis Survival 
Project, with support from the Lilly MDR‐TB 
Partnership. 
 
Mr. Smith, an epidemiologist and lecturer at Yale 
University, began working on the video 
documentary while conducting epidemiological 
research on multidrug-resistant (MDR) TB in the 
mining industry. With no film experience, but 
plenty of heart and determination, he worked two 
jobs to fund his trip to South Africa, where he 
spent several months living with four miners 
coinfected with TB and HIV. 
 
To view the documentary and related film clips 




—Submitted by Linette McElroy 
TB ETN 
 
TB PROGRAM EVALUATION 
NETWORK UPDATE 
 
Known HIV Status Evaluation Project 
in Colorado 
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Background 
The Colorado Department of Public Health and 
Environment (CDPHE) TB Program has 
statewide responsibility for the screening, 
treatment, and control of TB in that state. 
Colorado comprises 64 counties with populations 
ranging from several hundred to over half a 
million persons. For the years 2006 through 
2010, Colorado’s reported TB case counts were 
124, 111, 103, 85, and 71. There were 8 TB/HIV 
patients in 2006 (7.5% of total TB cases); 3 in 
2007 (3.3% of total), 2 in 2008 (2.2% of total), 4 
in 2009 (5.5% of total), and 8 in 2010 (8.8% of 
total), which was the highest annual percentage 
of co-infection in the previous decade. During 
2006-2010, the average prevalence rate of HIV 
infection among TB cases of all ages was 3.8%. 
Given that the majority of TB cases occurring in 
Colorado are among the foreign-born population, 
often coming from areas that are not only 
endemic with TB but also HIV, Colorado chose to 
develop an evaluation plan to improve the HIV 
testing rates to meet the national objective of 
88.7% by 2015. It is important to note that before 
the monitoring of “Known HIV Status” through the 
National Tuberculosis Indicators Project (NTIP) 
as a national objective, HIV testing was only 
stressed in those cases 15 years of age and 
older. 
 
Table 1. Annual HIV Testing Rates among Active 
TB Cases in Colorado, 2006–2011 



















2006 124 7 110 88.7 
2007 111 7 93 83.8 
2008 103 10 88 85.4 
2009 85 11 73 85.9 
2010 71 5 68 95.8 
2011* 69 8 61 88.4 
*Data are preliminary 
 
The goals of Colorado’s Known HIV Status 
evaluation project were to examine, evaluate, 
and improve TB control and prevention activities 
as they relate to HIV testing and known HIV 
status of all active TB patients in the state and to 
develop capacity building and technical 
assistance activities as needed for local health 
department staff. During 2010, the focus was on 
assessing the education and training needs of 
county health department TB control staff specific 
to HIV testing. The initial assumption was that 
there was a cohort of public health nurses, 
probably rural, that were uncomfortable with HIV 
testing and the discussion of risk behaviors 
(sexual and drug-taking), leading to lower-than-
desired HIV testing rates. As the survey results 
would show, we had much to learn. 
 
First Steps 
When the Deputy TB Program Manager joined 
the program in the summer of 2010, he was 
tasked with scaling up the HIV testing evaluation 
project. A line list of previous and current active 
TB cases with no accompanying HIV test result 
was created and analyzed in hopes of 
ascertaining trends or deficiencies in acquiring 
HIV test results from patients. The next step was 
developing a knowledge, attitudes, and practices 
(KAP) survey to administer to local health 
department TB staff related to HIV testing of 
active TB patients, with an eye toward informing 
the development of methods, activities, or 
policies to improve the HIV testing rate among 
active TB patients. 
 
The TB Program sought the expertise of Dr. 
Susan Luerssen, a member of the CDPHE 
HIV/STI Section’s Research and Evaluation Unit, 
to help develop a survey with succinct and 
measurable language that minimized ambiguity 
in the survey answers (the final survey questions 
are available at the TB-PEN wiki page 
http://tbpen.pbworks.com/w/page/4124488/Front
Page or from Pete Dupree at 
peter.dupree@state.co.us or 303-692-2677). 
Questions covered regional, institutional, and 
survey-takers’ personal capacity and beliefs 
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around HIV testing, as well as questions 
designed to probe for both individual and 
systemic barriers to HIV testing. A link to the 
confidential online survey was sent out to all TB 
Program partners throughout the state, with an 
explanation of why the survey was being offered 
and how the information would be used. In early 
2011, the survey was offered anonymously 
online for 2 weeks; 41 completed surveys were 
submitted and analyzed. 
 
Survey Results 
Addressing personal and agency capacity, only 
34% of the respondents personally provided HIV 
testing services in their role in TB control; 61% of 
the respondents noted that someone in their 
health department offered such services. For 
those respondents who stated that no HIV testing 
services were offered in their agency, the primary 
reason given was that another agency nearby 
offered it; the second most common reason was 
a lack of funding. When looking at established 
HIV testing policies and procedures, only 27% 
answered in the affirmative; another 27% said 
“do not know,” which is a concern in itself. Of the 
remaining 46%, a majority stated that they 
referred to CDPHE’s or the Denver Metro TB 
Clinic’s TB manual in such circumstances since 
their agency did not have such policies/ 
procedures regarding HIV testing of all active TB 
patients. Of those respondents whose agency 
offered HIV testing services, 35% offered 
conventional venipuncture testing using ELISA or 
Western Blot methodology, 46% offered rapid 
finger prick or oral transudate HIV testing, and 
the remainder gave differing answers such as 
“we let MD decide test type.” 
 
Survey Analysis 
Below is an excerpt from the responses to two 
key questions from the survey, followed by a brief 
analysis: 
 
The “no” responses are critical. Coupled with the 
responses to Question #11 below, we find that 
the TB Program has not been directive enough or 
has otherwise left the HIV testing imperative 
ambiguous. The 10 “Don’t Know” responses to 
this basic service are equally concerning. 
 
#1 response: The cost; two types of responses: 
1) expense to the local HD and 2) patient lacks 
funds to pay for an HIV test. 
#2 response: ignorance of HIV testing directive 
#3 response: no HIV or TB cases in county 
 
Scariest response: “We don’t get many active or 
latent cases so we don’t think to ask about HIV 
nor are we usually prompted by the state to do 
so.” 
 
When comparing these survey results to the 
table of annual HIV testing rates (Table 1), it’s 
apparent that the knowledge gap regarding the 
10. Is HIV testing offered to all patients with 
active TB disease at your agency? 
Yes 20 49% 
No 11 27% 
Don't Know 10 24% 
11. If no, please explain the circumstances under which a 
patient with active TB disease would not be offered an HIV test, 
or list any barriers your agency faces to offering HIV tests to all 
patients with active TB disease. 
19 total responses presented as the top 3 recurring themes 
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importance of HIV testing of all active TB patients 
is shrinking or has disappeared entirely, and that 
our assumptions that there was HIV testing 
resistance from some nurses was completely 
wrong. Given the findings here, a clear and 
concise policy on HIV testing of active TB 
patients is needed to avoid any further confusion. 
There were repeated responses that some 
survey-takers were unaware of any HIV testing 
requirement. The fault for this falls to CDPHE’s 
TB Program. 
 
It is necessary to make abundantly clear what’s 
expected of TB case managers, public health 
nurses, and even primary care providers caring 
for TB patients. Simply put, if they are offering 
care and treatment to a patient with active TB 
disease, that patient should be offered and given 
an HIV test as a part of his/her continuum of care 
(or there needs to be a recorded HIV test result 
in the past 3 months). 
 
This policy might be framed as a protocol, 
complete with an algorithm to guide the TB/public 
health staff. The protocol should guide the staff 
person through different scenarios, such as the 
patient has no primary care provider; the health 
department has neither in-house HIV testing 
services nor funds for off-site testing; or the 
patient cannot pay out of pocket yet has no 
health insurance. With HIV testing, CDPHE will 
begin to meet one of its key program evaluation 
objectives, “Active TB patients without a recent 
(last 3 months) HIV test result will be identified 
and addressed by TB Program staff (via RVCTs 
and/or weekly Case Management) with the 
appropriate TB nurse case manager overseeing 
that patient’s care and treatment.” 
 
It may ultimately suffice to simply continue the 
chorus loud and clear—the HIV status of every 
active TB patient in Colorado will be known, 
regardless of patient age, race, gender, 
socioeconomic status, or country of origin, based 
on established medical and public health 
standards. It is unacceptable to discover, late in 
the regimen of a patient who is not improving, 
that the patient is and has been HIV-infected 
during treatment. If a patient refuses an HIV test, 
at least it can be assured they’ve been given the 
opportunity to be tested; they would have to sign 
a waiver stating that they’d been given 
educational material about the importance of 
knowing one’s HIV status, a copy of which would 
be kept by the TB Program. Their documented 
refusal would be prefaced by the educational 
component highlighting the dangers of 
coinfection such that the TB patient can make an 
informed decision about his/her long-term health. 
An HIV test result available in 20 minutes via 
rapid testing would be an enticement to those 
unsure or ambivalent about being tested.  
 
Survey Limitations 
Because this was an anonymous KAP survey, it’s 
not possible to assess how many respondents 
came from large urban TB clinics, with 
experienced case management skills due to a 
consistent volume of TB cases, and how many 
came from more rural public health agencies 
working with smaller populations that don’t see a 
high volume of active TB or HIV. This was a 
convenience survey and may not be 
representative of the statewide TB control staffs’ 




An HIV testing policy is being incorporated into 
the updated CDPHE TB Manual that is currently 
being drafted by Colorado’s TB Program. A 
referral network for agencies not offering HIV 
testing is being considered and a laboratory HIV 
testing courier service (using the existing TB 
specimen courier service) is being developed. 
The courier service would transport whole blood 
to the state lab for HIV testing in a timely manner 
in situations where the local health department 
nor nearby agencies have a rapid HIV testing 
capacity. 
 
—Submitted by Pete Dupree, MPH 
Colorado Dept of Public Health and Environment 
TB PEN 







Communicating the New 12-Dose 
Latent TB Infection Treatment 
Regimen 
 
DTBE’s Communications, Education, and 
Behavioral Studies Branch (CEBSB) developed 
and updated a variety of communication and 
education materials in preparation for the release 
of the 12-dose treatment regimen guidelines for 
latent TB infection in the Dec. 9, 2011, Morbidity 
and Mortality Weekly Report (MMWR). 1 
 
CEBSB provided TB controllers and other 
partners with key messages to assist them in 
communicating the new guidelines and 
developing their own talking points. Additionally, 
CEBSB developed several communication 
products and updated Web pages to provide 
health care professionals and the general public 
with information about the new regimen. These 
materials are available on the DTBE web site.  
 
Specific highlights included two matte articles 
targeting the general public and health care 
professionals. Matte articles are ready-to-print 
articles that can be used in any publication or 
customized with additional information for 
publication.  
 
CDC Issues Shorter Treatment Regimen for 




New Regimen Makes Treating TB Infection 
Easier-Matte Article  
(www.cdc.gov/tb/publications/matte_articles/12D
ose_GeneralPublic.pdf) 
DTBE’s Director, Dr. Kenneth Castro, also 
recorded a video podcast for health care 
professionals related to the guidelines. This video 
is available in English and Spanish. 
 
New Treatment Regimen for Latent Tuberculosis 
Infection-Video Podcast 
 
 English version 
(www.cdc.gov/tb/topic/treatment/12dose_vid
eo.htm) 
 Spanish version 
(www.cdc.gov/tb/topic/treatment/12dose_vid
eo_es.htm)  
In the days following the release of the 
guidelines, CEBSB staff worked with social 
media experts to develop “tweets” for Twitter and 
messages for Facebook. The CDC.gov 
homepage also prominently displayed a feature 
about the 12-dose regimen. This feature article is 
available in English and Spanish. 
 
New, Simpler Way to Treat Latent TB Infection–
CDC Web Feature 
(www.cdc.gov/Features/TuberculosisTreatment/)  
 
Spanish Version - (Español) 
(www.cdc.gov/spanish/especialesCDC/Tratamien
toTB/) 
Additionally, multiple Web pages were updated to 





Treatment for Latent TB Infection 
(www.cdc.gov/tb/topic/treatment/ltbi.htm)  
Treatment Options for Latent Tuberculosis 
Infection 
(www.cdc.gov/tb/publications/factsheets/treatme
nt/LTBItreatmentoptions.htm)   
Targeted Tuberculosis (TB) Testing and 
Treatment of Latent TB Infection-Slide set 





CEBSB will continue to update and develop new 




CDC. Recommendations for use of an isoniazid-
rifapentine regimen with direct observation to treat 
latent Mycobacterium tuberculosis infection. MMWR 




—Reported by Nicole Richardson-Smith, MA 
Div of TB Elimination 
 
TB 101 for Health Care Workers 
 
Background 
TB 101 for Health Care Workers is a web-based 
course designed to educate health care workers 
about basic concepts related to TB prevention 
and control in the United States. TB 101 was 
developed as a collaborative effort between 
CDC’s Division of Tuberculosis Elimination 
(DTBE) and the four CDC-funded TB Regional 
Training and Medical Consultation Centers 
(RTMCCs): the New Jersey Medical School 
Global TB Institute, the Southeastern National TB 
Center, the Heartland National TB Center, and 
the Curry International TB Center.  The need for 
an online basic TB course for persons new to the 
field of TB and persons working in related health 
fields (e.g., HIV/AIDS and STD programs, 
correctional healthcare) was identified through a 
review of both formal and informal TB training 
and education needs assessments conducted by 
CDC and the RTMCCs. A multi-phased, 
systematic health education process was utilized 
for the development of this course. 
Target Audience 
The target audience for the course includes 
newly hired TB program staff, HIV/AIDS and STD 
staff, and health care workers in areas related to 
TB. Due to its introductory-level content, 




The course consists of six lessons: 
 
1. Introduction 
2. TB Transmission and the Development of TB 
Disease 
3. Testing for TB Infection 
4. Diagnosis of TB Disease 
5. Treatment of Latent TB Infection 
6. Treatment of TB Disease 
 
The course also includes interactive case studies 
and study questions throughout each lesson to 
reinforce key concepts. 
 
TB 101 takes approximately 1 hour to complete.  
 
Participant Feedback on the Course 
As of March 1, 2012, approximately 1,300 
participants have completed the course since its 
release on January 5, 2012. Of these 
participants, 977 completed the course for 
continuing education (CE) units. Participant 
feedback from the CE course evaluation has 
been overwhelmingly positive.  
 
Select Course Evaluation Results 
Evaluation Question % Answer 
The content and learning 
materials addressed a need 




Delivery method used helped 
me learn the content. 
96% Strongly 
Agree/Agree 
If given an opportunity, I can 
apply the knowledge gained 
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Summary of Comments from Participants 
Overall, many participants found the course 
content to be clear, concise, and easy to 
understand. Below are a few select comments 
from course participants: 
• “Excellent format and information. I plan to 
assign this activity to my staff.” 
•  “Appropriate and easy to learn from this 
technique.” 
• “The content and learning material was very 
good for someone new to TB and was very 
current for someone with TB experience.” 
• “Excellent introduction to TB.”  
• “I felt the content was a fabulous refresher 
for me. Highlighted on important things.” 
• “Case studies were excellent.” 
 
Accessing the Course and Continuing Education 
To access the TB 101, please visit the CDC 
website: www.cdc.gov/tb/webcourses/tb101. 
 
Continuing education (CE) units for this course 
are offered free of charge for various professions:  
 
• Continuing education units (CEUs):  CDC 
has been approved as an Authorized 
Provider by the International Association for 
Continuing Education and Training (IACET), 
1760 Old Meadow Road, Suite 500, McLean, 
VA 22102. The CDC is authorized by IACET 
to offer 0.1 ANSI/IACET CEUs for this 
program. 
 
• Continuing nursing education (CNEs): 
CDC is accredited as a provider of 
Continuing Nursing Education by the 
American Nurses Credentialing Center’s 
Commission on Accreditation. This activity 
provides 1.1 contact hours. 
 
• Continuing education contact hours 
(CECHs):  Sponsored by CDC, a designated 
provider of CE contact hours (CECHs) in 
health education by the National Commission 
for Health Education Credentialing, Inc. This 
program is designed for Certified Health 
Education Specialists (CHES) to receive up 
to 1.0 Category I CECHs in health education. 
CDC provider number GA0082. 
 
More information about the CE units is available 
at: www.cdc.gov/tb/education/CE/tb101.htm.  
 
—Submitted by Sarah Segerlind, MPH 
Division of TB Elimination 
 
INTERNATIONAL RESEARCH 
AND PROGRAMS BRANCH 
UPDATES 
 
The Preserving Effective TB 
Treatment Study 
 
Antibacterial drugs are a two-edged sword. While 
they destroy pathogenic bacteria, they also select 
for drug-resistant bacteria against which those 
drugs are ineffective. In public health, one of the 
gravest examples is the worldwide emergence of 
multidrug-resistant (MDR) and extensively drug-
resistant (XDR) tuberculosis (TB). Global 
surveillance has revealed drug-resistant TB to be 
widespread and a threat to TB control in many 
countries. Treating MDR TB is imperative to 
prevent further spread; however, the high cost of 
second-line drugs (SLDs) severely limits their 
use. On the other hand, increasing access to 
costly SLDs has the potential to hasten the 
development of resistance to these same drugs. 
To address this issue, in 2000 the World Health 
Organization (WHO) and the Stop TB 
Partnership formed the Green Light Committee 
(GLC), a subgroup of the International Working 
Group on MDR TB. By carefully evaluating and 
assisting proposed MDR TB programs to ensure 
they would use the second-line drugs optimally, 
the GLC aims to increase access to these TB 
drugs while at the same time preventing the 
emergence of resistance. 
 
The Preserving Effective TB Treatment Study 
(PETTS) is a prospective cohort study that is 
being conducted to evaluate the extent to which 
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the GLC mechanism prevents acquired 
resistance to second-line drugs. It is the largest 
prospective study of MDR TB ever carried out. 
The study was designed to compare the 
frequency and consequences of acquired 
resistance to second-line drugs in MDR TB 
patients between projects approved by Green 
Light Committee and other MDR TB treatment 
programs (non-GLC). PETTS was conducted in 9 
countries (Peru, Russia, Latvia, Estonia, South 
Africa, Thailand, Philippines, South Korea, and 
Taiwan) from 2005 to 2010. The amplification of 
drug resistance was determined by examining 
the drug-susceptibility testing (DST) results and 
genotypes of each patient’s last positive culture 
compared with the same patient’s pretreatment 
isolate. Enrollment of patients in PETTS ended in 
December 2008, and follow-up ended in June 
2010. Patients’ isolates of M. tuberculosis were 
shipped to CDC, where the laboratory carried out 
DST for all baseline and final isolates. 
Genotyping and data analysis are ongoing. The 
first round of DNA fingerprinting is being 
completed in March 2012. 
 
Preliminary results indicate that baseline 
prevalence of drug resistance was similar in 
GLC-approved and non-GLC projects except for 
the GLC site in the Philippines, which had a low 
prevalence of baseline drug resistance. However, 
acquired resistance to fluoroquinolones and 
second-line injectable drugs was lower in the 
GLC sites among the first 550 patients with 
testing completed. These preliminary results 
need to be extended with the rest of the patients 
and confirmed with genotyping. Finally, cure 
rates were higher, while mortality and treatment 
failure were lower, in GLC-approved projects 
compared with non-GLC projects; mortality 
remained lower in GLC projects after exclusion of 
HIV-infected patients, the majority of those being 
from South Africa, a non-GLC site. 
 
—Reported by Peter Cegielski, MD, MPH, 
Ekaterina Kurbatova, MD, MPH, PhD, 
Tracy Dalton, PhD, and Julia Ershova, PhD 
Div of TB Elimination 
Tuberculosis Genetic Lineage and 
Clinical Site of Disease 
 
Dr. Robert Koch’s discovery of the tubercle 
bacillus over 100 years ago opened the door to 
laboratory investigation of the bacterium that 
causes TB. Despite this long history of 
investigation, an understanding of the genetics of 
the bacterium that causes most TB in humans, 
Mycobacterium tuberculosis, largely remained 
elusive until recently. Over the past several 
years, genetic features of M. tuberculosis 
isolated from patients in many different places in 
the world have been compared. This work has 
resulted in the surprising finding that there are 
four principal genetic sub-groups of M. 
tuberculosis, and that these sub-groups are 
primarily found in different regions of the globe.1 
These four principal sub-groups, or lineages, of 
M. tuberculosis are each named for the region of 
the world in which they predominate: Euro-
American, Indo-Oceanic, East African Indian, and 
East Asian. 
 
Individual strains of M. tuberculosis bacteria vary 
genetically. Variation between individual bacterial 
strains allows genotyping such as is performed 
by the National Tuberculosis Genotyping Service 
in the United States.2,3 It is this variation between 
strains which makes it possible to determine 
whether cases of TB in a local jurisdiction, for 
example, are likely to be part of the same chain 
of transmission. However, despite this variation 
between strains of M. tuberculosis, strains 
isolated from individual patients can be 
categorized as belonging to one of the four 
primary lineages according to genotyping 
information that is characteristic for each of the 
four lineages. 
 
The finding that there are four principal genetic 
subgroups of M. tuberculosis raises the question: 
is the clinical disease caused by these sub-
groups different? This question is important, 
because clinical differences could affect control 
and treatment strategies, including development 
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of novel approaches to therapy and TB 
vaccines.1 
 
The January 15, 2012, issue of Clinical Infectious 
Diseases contains an article describing an 
analysis aimed at understanding whether cases 
of TB caused by the four principal lineages of M. 
tuberculosis differ by clinical site of disease.4 
Although TB is primarily a disease of the lungs, 
virtually any organ system can be involved; 
however, factors that determine where disease 
occurs in the body are not well understood.  
Using data from the National Tuberculosis 
Genotyping Service linked to National 
Tuberculosis Surveillance System data, the 
authors analyzed 32,000 cases of TB reported 
during 2004–2008.  Because of the diversity of 
patients with TB in the United States, with more 
than half born in other countries, these data 
provide a rich source of information on diverse 
strains from all four of the principal lineages. This 
study found that compared with the other 
lineages (East African Indian, Indo-Oceanic, and 
Euro-American), the East Asian lineage of M. 
tuberculosis (also known as the Beijing family) 
was associated with pulmonary disease more 
than with extrapulmonary disease. 
 
This study contributes to a growing body of 
literature suggesting that there are differences in 
associated clinical disease between lineages.5,6 
Recently, the East Asian lineage has elicited 
particular interest as some investigators have 
suggested it is spreading globally.7 Because 
pulmonary TB is the infectious form of the 
disease, the finding that patients infected with 
this lineage more commonly develop pulmonary 
disease would be consistent with increased 
transmissibility of this lineage. This area of study, 
increasing our understanding of TB biology, is 
needed to improve diagnostic tests and 
prevention and treatment strategies, including 
drugs and vaccines.8 
 
—Reported by Eleanor Click, MD 
Div of TB Elimination 
 
References 
1. Gagneux S, Small PM. Global phylogeography of 
Mycobacterium tuberculosis and implications for 
tuberculosis product development. Lancet Infect 
Dis 2007; 7:328-37. 
2. Ghosh S, Moonan PK, Cowan L, Grant J, 
Kammerer S, Navin TR. Tuberculosis 
Genotyping Information Management System: 
Enhancing Tuberculosis Surveillance in the 
United States. Infect Genet Evol 2011. 
3. CDC. New CDC program for rapid genotyping of 
Mycobacterium tuberculosis isolates. MMWR 
2005; (54):47. 
4. Click ES, Moonan PK, Winston CA, Cowan LS, 
Oeltmann JE. Relationship between 
Mycobacterium tuberculosis phylogenetic lineage 
and clinical site of tuberculosis. Clin Infect Dis 
2012; 54:211-9. 
5. Coscolla M, Gagneux S. Does M. tuberculosis 
genomic diversity explain disease diversity? Drug 
Discov Today Dis Mech 2011; 7:e43-e59. 
6. Kato-Maeda M, Nahid P. Mycobacterium 
tuberculosis lineage--what's in your lungs? Clin 
Infect Dis 2012; 54:220-4. 
7. Parwati I, van Crevel R, van Soolingen D. 
Possible underlying mechanisms for successful 
emergence of the Mycobacterium tuberculosis 
Beijing genotype strains. Lancet Infect Dis 2010; 
10:103-11. 
8. Comas I, Gagneux S. A role for systems 
epidemiology in tuberculosis research. Trends 





Molecular Detection of Drug 
Resistance Clinical Service 
 
Rapid and accurate identification of drug-
resistant TB is essential for control and 
prevention of TB. Science and technology have 
merged to produce new diagnostic testing 
options for the detection of drug-resistant TB; 
however, these molecular assays are not 
currently widely available. Therefore, DTBE’s 
Laboratory Branch consolidated available 
knowledge, conducted translational research and 
development to assemble a molecular testing 
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platform, and implemented a clinical service that 
provides rapid information about drug resistance 
to clinicians.  
 
Research and development included a 
comprehensive survey of nine genetic loci known 
to harbor mutations associated with resistance to 
both first-line and second-line anti-tuberculosis 
drugs in over 300 isolates of Mycobacterium 
tuberculosis.  The resultant genotypic data set 
was compared with culture-based drug-
susceptibility data to determine accuracy for each 
locus.  These values served as the analytic basis 
for the molecular detection of drug resistance 
(MDDR) clinical service.  Since September 2009, 
the Laboratory Branch has offered the MDDR 
service nationally to patients and their providers.  
The service detects mutations associated with 
resistance to eight first-line and second-line TB 
drugs; average turnaround time is 2 days, 
compared to the turnaround time of 28–35 days 
for culture-based methods. It provides rapid 
detection of drug resistance or confirmation of 
known drug resistance and provides information 
that may be used by clinicians to guide therapy 
decisions.  The service has been well received 
by the public health community and has been 
used by 47 states and territories. Currently, the 
Laboratory Branch is validating a new method for 
detecting mutations associated with rifampin and 
isoniazid resistance in patient specimens known 
to contain M. tuberculosis as determined by 
amplification-based assays.  This addition to the 
MDDR service is scheduled to begin in early 
2012.  
 
In addition to affecting patient management 
decisions, the results provided by the MDDR 
clinical service also affect those related to 
infection control and public health interventions.  
Rapid confirmation of drug-resistant TB and 
guidance on selection of an effective drug 
regimen will reduce delay in the adequate 
treatment of TB and could translate into 
decreased transmission of TB. 
 




—Reported by Bonnie Plikaytis 
Div of TB Elimination 
 
Review of Southeastern 
Mycobacteria Meeting 
 
The fourth bi-annual Southeastern Mycobacteria 
Meeting took place January 14, 2012, at Emory 
University’s Claudia Nance Rollins Building.  
Attendees came from academia, government, 
and industry, representing Emory University, 
University of Georgia, University of North 
Carolina at Chapel Hill, Duke University, 
Research Triangle Institute, University of 
Louisiana-Lafayette, Health Sciences Center of 
Louisiana State University, Southern University 
at New Orleans, University of Alabama at 
Birmingham (UAB), Tulane National Primate 
Research Center, Tulane University, University of 
Florida, and CDC.  Post-doctoral fellows and 
graduate students were especially encouraged to 
present their work in posters and oral 
presentations. 
 
The day’s agenda included a series of short talks 
presenting ongoing research projects and two 
poster sessions.  In one talk, Ruth Napier, a 
graduate student at Emory University, presented 
her work demonstrating utility of an ABL-family 
tyrosine kinase inhibitor (imatinib) in reducing M. 
tuberculosis entry and survival within 
macrophages.  Frank Wolschendorf from UAB 
described research using M. tuberculosis 
sensitivity to copper as a possible new 
therapeutic.  His most recent experiments 
included a high throughput screen to identify 
compounds that could affect copper poisoning of 
M. tuberculosis.  Graduate student Meghan 
Feltcher from UNC described her recent attempts 
to decipher the M. tuberculosis SecA2 protein 
translocation system.  She demonstrated that 
unlike proteins exported through the traditional 
Sec system, those exported via SecA2 do not 
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contain a signal sequence and are targeted to 
the SecA2 pathway by the mature protein 
sequence.  She also showed that although the 
two SecA2 substrates thus far identified are 
lipoproteins, lipid modification is not a requisite 
for SecA2 export. 
 
The keynote address, given by Eric Rubin, MD, 
PhD, of Harvard University, was titled, “Protein 
synthesis and degradation in mycobacteria: lost 
in mistranslation.”  Dr. Rubin described a new, 
cutting-edge technique that will enable the role(s) 
of individual mycobacterial proteins to be 
explored via targeted proteolysis. He also 
presented data on protein mistranslation in 
mycobacteria and its possible consequences, 
including implications for drug resistance. 
 
Laboratory Branch Chief Michael Iademarco, 
MD, MPH, gave a presentation describing the 
role of CDC’s National Laboratory in TB 
elimination.  Members of the Laboratory Branch 
Applied Research Team (Seidu Malik, Subhi 
Nandakumar, Suraj Sable, and Melisa Willby) 
presented posters detailing current research 
projects. 
 
This excellent regional meeting brought together 
a diverse group of individuals conducting 
research on a wide variety of topics in 
mycobacteria to foster information exchange and 
collaborative opportunities. 
 
—Submitted by Melisa Willby, PhD 







First Semi-annual Tuberculosis 
Epidemiologic Studies Consortium II 
Meeting 
 
On December 8–9, 2011, the first semi-annual 
meeting of the newly constituted Tuberculosis 
Epidemiologic Studies Consortium (TBESC) took 
place in Atlanta at the Crowne Plaza Ravinia.  
This was the first opportunity for the newly 
selected TBESC sites and CDC staff to be 
introduced and to get down to work!  The 
following sites were selected to be part of the 
new TBESC and were present in Atlanta: 
• California Department of Public Health 
• Denver Health and Hospitals Authority  
• Duke University 
• Emory University 
• Hawaii Department of Health 
• Maricopa County Department of Public 
Health 
• Maryland Department of Public Health 
• Public Health Seattle-King County 
• University of Florida Board of Trustees 
• University of North Texas Health Science 
Center 
 
The goals of the meeting were for Consortium 
members and CDC staff to discuss the Task 
Order 1 (TO 1) study protocol, the new structure 
of the Consortium, and the data collection 
instruments.  The meeting kicked off with a warm 
welcome to all sites from Denise Garrett, MD, 
CDC project officer for TBESC.  She also 
outlined the structure for the 2-day meeting, 
which focused more on round-table discussions 
than prior TBESC meetings.  Dr. Garrett 
encouraged all meeting participants to actively 
engage in the discussions.  
 
Three main areas of the study protocol were 
presented by Tom Navin, MD, Chief of the 
Surveillance, Epidemiology, and Outbreak 
Investigations Branch.  After outlining each topic, 
he invited feedback and advice from everyone 
present.  In addition to the discussions 
surrounding the protocol, Dolly Katz, PhD, 
reviewed the study objectives with the group.  
The main objectives are to evaluate and compare 
the performance of tuberculin skin tests (TSTs) 
and interferon gamma release assays (IGRAs) in 
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1) diagnosing LTBI, and 2) predicting progression 
from LTBI to TB disease, overall and among 
important subgroups of patients.  Dr. Katz also 
spoke to the Consortium about the study’s 
expected sample size and answered questions 
regarding these calculations. 
 
An additional component of TO 1 is to compare 
the costs, cost differences, and cost-
effectiveness of IGRAs and TST. Suzanne 
Beavers, MD, led this discussion and placed 
emphasis on how the Consortium plans to collect 
cost data and the importance of translating these 
findings to the program level. 
 
The second day of the meeting was led by 
Meredith Howley, MS, and Melissa Pagaoa, 
MPH. They presented the data collection 
instruments and sought feedback on how best to 
develop the forms in order to answer the 
objectives outlined on the first day. Julio Lopez 
and Arnette Mayhew from CDC’s Procurements 
and Grants Office addressed the Consortium and 
answered contractual and invoicing questions. 
 
Overall, the meeting was a great success!  The 
teamwork and camaraderie expressed by CDC 
staff and Consortium sites resulted in productive 
discussions that were fruitful and helped further 
define the study objectives and procedures.  We 
look forward to enjoying a very productive 
collaboration with all TBESC members and 
seeing all of our new colleagues again in June 
2012 for the second semi-annual meeting of 
TBESC II. 
 
—Reported by Meredith Howley, MS, 
and Melissa Pagaoa, MPH 
Div of TB Elimination 
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Sekai Chideya, MD, has returned to DTBE as a 
member of the Surveillance, Epidemiology, and 
Outbreak Investigations Branch. She has joined 
the TBESC team as a Medical Epidemiologist, 
returning to DTBE from the Global AIDS 
Program, where she had been working on 
implementation of a medical male circumcision 
program.  Prior to that, Sekai was a Medical 
Director at the NYC Department of Health and 
Mental Hygiene. During 2005–2007, Sekai 
served as an EIS Officer with DTBE’s 
International Research and Programs Branch. 
 
Panayotta Delinois, MS, has joined the 
Reference Laboratory Team of the Laboratory 
Branch as an ORISE Fellow. In this capacity she 
will assist with the expanding Molecular 
Detection of Drug Resistance service. She 
earned her MS degree in Microbiology and 
Immunology from New York Medical College in 
2009. Previously, she worked as the TB Program 
Specialist for the Association of Public Health 
Laboratories (APHL), where she primarily helped 
to provide logistical support for the 7th National 
Conference on Laboratory Aspects of 
Tuberculosis. 
 
Sonya Garnett, Program Specialist in the Office 
of the Director, is the worthy recipient of the 
DTBE Director’s Recognition Award for the first 
quarter of 2012. Sonya was selected to receive 
this honor because of her impeccable 
professionalism, dedication, and work ethic; her 
outstanding organizational skills; and her 
exceptional performance, including her 
willingness to work after hours to go the "extra 
mile" to anticipate and meet tight and demanding 
deadlines. In all her roles and interactions, Sonya 
serves as a role model of excellence. This 
combination of skills, attributes, and commitment 
makes her deserving of the Director’s 
Recognition Award. Congratulations to Sonya for 
this well-deserved honor. 
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Paige Gupton, MS, has joined the Laboratory 
Branch Reference Laboratory Team as an 
ORISE Fellow. In this capacity she will assist with 
the expansion of the Molecular Detection of Drug 
Resistance clinical service. Paige moved to 
Atlanta from Washington, D.C., where she 
earned a MS degree in Public Health 
Microbiology at George Washington University 
(GW), and worked in a lab as a Research 
Assistant. Her primary area of research at GW 
was HIV diagnostics in limited resource settings. 
Prior to attending GW, Paige worked for NCEZID 
in the Division of Parasitic Diseases as a 
Laboratory Technician in the Serology 
Diagnostics Laboratory. 
 
Alexandra (Alex) Mercante, PhD, has joined the 
Applied Research Team of the Laboratory 
Branch as an Associate Service Fellow.  In this 
capacity, she will be investigating both 
transcriptional regulation and protein modification 
to help gain new insights concerning antibiotic 
resistance mechanisms in Mycobacterium 
tuberculosis.  Alexandra received her BS degree 
in Microbiology from Louisiana State University in 
2000 and subsequently worked as a research 
technician in both private industry and academic 
institution laboratory settings. Recently, she 
earned a PhD in Microbiology and Molecular 
Genetics from Emory University. Under the 
guidance of her graduate mentor, Dr. William 
Shafer, she examined how host factors modulate 
the molecular mechanisms that regulate 
antibiotic resistance determinants in Neisseria 
gonorrhoeae. 
 
Nwabunie Nwana is a first-year student at the 
Rollins School of Public Health, Emory 
University. In 2009, she received her bachelor's 
degree in biochemistry, chemistry, and 
environmental studies from Wartburg College, 
Waverly, Iowa. As an undergraduate, she 
interned with the TB control unit of the World 
Health Organization (WHO) in Nigeria. Since that 
time, she has developed a strong interest in the 
prevention and control of infectious diseases. 
She is very excited about contributing to the 
control and eventual eradication of TB, and looks 
forward to working with FSEB staff.  
 
Chaturia Rouse has joined DTBE in the 
Surveillance, Epidemiology, and Outbreak 
Investigations Branch. She is working on the 
TBESC team as a public health analyst 
contractor from Northrop Grumman. Previously 
Chaturia worked at Boston Medical Center, 
where she carried out data coding, cleaning, and 
analysis for the Massachusetts Screening, Brief 
Intervention, Referral and Treatment (MASBIRT) 
Program. 
 
Erika Sigman, MS, of the Laboratory Branch (LB) 
recently transitioned from her position as an 
ORISE Fellow to an associate Service Fellow. 
She joined the LB as an ORISE Fellow after 
graduating from Emory University in 2008. In that 
position, she worked in the Genotyping Activity, 
where she performed molecular screening to 
help determine the relationship of human genetic 
factors to TB pathogenesis.  After receiving her 
MS degree in biology from Georgia Institute of 
Technology in 2011, she was offered and 
accepted an associate Service Fellow position 
with the LB. She will help carry out various 
genotyping activities within the Applied Research 
Team of the Laboratory Branch. 
 
Caroline Tai has joined the Laboratory Capacity 
Team of the Laboratory Branch as a Research 
Assistant as part of the Rollins Practical 
Experience Program. She will support the team 
in analyzing data from operational studies to 
build and maintain laboratory capacity for 
tuberculosis. Caroline gained laboratory 
experience from working in the biotech industry 
in San Diego, California, where she also earned 
her BS degree in microbiology at the University 
of California, San Diego. She is currently 
pursuing an MPH degree in epidemiology at the 
Rollins School of Public Health of Emory 
University. 
 
Taiwo Talabi, MD, is a second-year student at 
the Rollins School of Public Health, Emory 
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University. He graduated in November 2006 with 
a medical degree from the College of Medicine of 
the University of Lagos, Nigeria, and has been a 
practicing physician since graduation. He has 
been involved in active management and 
treatment of many infectious diseases, including 
TB, HIV, and hepatitis. During his time with the 
Medical Service Team of FSEB, he hopes that he 
will be able to learn much more and contribute 
significantly to the success of the team. 
 
Liping Zhu has joined DTBE as a member of the 
Surveillance, Epidemiology, and Outbreak 
Investigations Branch. Liping joined the TBESC 
team as a scientist data analyst as a Northrop 
Grumman contractor 4 months ago. Previously, 
she worked at Emory as a research specialist for 
about 10 years. She has many years’ experience 




ShaJuan Colbert, PhD, MPH, passed away 
unexpectedly on February 2, 2012. She had 
worked in the NCHHSTP Office of Health Equity 
(OHE) from summer 2010 to April 2011. During 
her time in OHE, ShaJuan made a number of 
significant contributions to promoting health 
equity within NCHHSTP.  She led OHE’s efforts 
on the Social Determinants of Health (SDH) 
Guidance for Surveillance Systems, the 2010 
and 2011 Health Equity Symposia planning, and 
SDH and health equity awareness slides for 
NCHHSTP colleagues. In addition, she drafted 
key documents such as Frequently Asked 
Questions and a Glossary of Terms for SDH. 
 
Prior to her assignment in OHE, she worked in 
the NCHHSTP Division of Tuberculosis 
Elimination (DTBE). ShaJuan joined DTBE’s 
Communications, Education, and Behavioral 
Studies Branch in May 2009 as a Behavioral 
Scientist. Her work in DTBE included planning, 
developing, implementing, and evaluating 
behavioral studies, projects, and research. 
ShaJuan contributed to the Advisory Council for 
the Elimination of Tuberculosis (ACET) African 
American Workgroup’s Strategic Plan, facilitating 
several group discussions with Workgroup 
members about goals and objectives of the 
strategic plan. She participated materially in 
conference calls, protocol reviews, and other 
tasks related to a HRSA/Minority AIDS Initiative 
Houseball LTBI Treatment Project with another 
DTBE branch. She also participated in TB 
Epidemiologic Studies Consortium Task Order 
23, which involved providing technical assistance 
to the Project Officer, reviewing and revising an 
interview guide, and participating in interviewer 
training in New Jersey. In summer 2010, she left 
DTBE for a detail in OHE. 
 
ShaJuan received an MPH degree from Emory 
University (2001) in Behavioral Sciences and 
Health Education. She received a PhD degree in 
Public Health (December 2008) from Michigan 
State University, focusing on Health Behavior 
and Health Education.  From 2001 to 2005, she 
worked with the Michigan Department of 
Community Health’s HIV/AIDS surveillance unit, 
where she served as the Project Study 
Coordinator on CDC-funded projects that 
included research with HIV-infected persons or 
persons in HIV behavioral risk groups (including 
injection drug use).  She also served as the HIV 
Behavioral Surveillance Coordinator for the 
Michigan Department of Community Health’s 
HIV/AIDS Epidemiology Unit.  While working as a 
doctoral student at the University of Michigan’s 
School of Public Health, she was a member of a 
group of researchers funded to focus on the 
behavioral, genetic, and biological markers of 
cardiovascular disease and mental health 
disorders, which also included exploring 
pathways of other prominent health disparities.  
After completing her doctorate, she had worked 
as an independent public health consultant 
before coming to CDC. 
 
ShaJuan was a friend to many at CDC. Her 
sincere dedication to and enthusiasm for 
promoting health and health equity will be greatly 
missed. She is survived by her husband, Andre 
Johnson; daughter, Ayanna Johnson; mother, 
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Laverne; father, Vincent; sisters Clarissa and 
Sonja; and other family members.  An 
educational fund in her name has been arranged 
for her daughter and adopted nephews.  At the 
request of the family, donations can be made to 
the Dr. ShaJuan Colbert Johnson Foundation.  
Checks can be made to her mother, Laverne 
Colbert, with the notation of “Dr. ShaJuan Colbert 
Johnson Foundation” in the memo portion of the 
check and mailed to 6258 Eastbrooke, West 
Bloomfield MI 48322. 
 
CALENDAR OF EVENTS 
 
March 22, 2012 
CDC World TB Day Observance 
Atlanta, GA, CDC Roybal campus 
CDC/DTBE 
 
March 24, 2012 
CDC 6th Annual TB Awareness Walk 
Atlanta, GA, Grant Park 
CDC/DTBE 
 
March 29–30, 2012 
American Epidemiological Society Annual 
Meeting 
Berkeley, CA 
American Epidemiological Society  
 
April 11–14, 2012  
The Denver TB Course 
Denver, Colorado 
National Jewish Health 
 
April 16–20, 2012  
EIS Conference 
Atlanta, GA 
Centers for Disease Control & Prevention (CDC)   
 
May 13–18, 2012 
2012 Keystone Symposia 
Kampala, Uganda 
Keystone Symposia   
 
May 14–15, 2012 
46th Annual CTCA Educational Conference  
Los Angeles, CA 
CTCA 
 
May 18–23, 2012 
ATS International Conference 
San Francisco, CA 
American Thoracic Society (ATS) 
  
May 20–23, 2012 




June 12–14, 2012 
2012 National TB Conference 
Atlanta, GA 
Sherry Brown  
